In/IN
silico/NN
approach/NN
to/TO
calculate/VB
the/DT
transcript/NN
capacity/NN
./.
====================
We/PRP
sought/VBD
the/DT
novel/JJ
concept/NN
,/,
transcript/NN
capacity/NN
(/(
TC/NN
)/)
and/CC
analyzed/VBD
TC/NN
./.
====================
Our/PRP$
approach/NN
to/TO
estimate/VB
TC/NN
was/VBD
through/IN
an/DT
in/FW
silico/NN
method/NN
./.
====================
TC/NN
refers/VBZ
to/TO
the/DT
capacity/NN
that/DT
a/DT
transcript/NN
exerts/VBZ
in/IN
a/DT
cell/NN
as/IN
enzyme/NN
or/CC
protein/NN
function/NN
after/IN
translation/NN
./.
====================
We/PRP
used/VBD
the/DT
genome-wide/NN
association/NN
study/NN
(/(
GWAS/NN
)/)
beta/NN
effect/NN
and/CC
transcription/NN
level/NN
in/IN
RNA-sequencing/JJ
to/TO
estimate/VB
TC/NN
./.
====================
The/DT
trait/NN
was/VBD
body/NN
fat/NN
percent/NN
and/CC
the/DT
transcript/NN
reads/VBZ
were/VBD
obtained/VBN
from/IN
the/DT
human/JJ
protein/NN
atlas/NNS
./.
====================
The/DT
assumption/NN
was/VBD
that/DT
the/DT
GWAS/NN
beta/NN
effect/NN
is/VBZ
the/DT
gene/NN
’/CD
s/NNS
effect/NN
and/CC
TC/NN
was/VBD
related/JJ
to/TO
the/DT
corresponding/JJ
gene/NN
effect/NN
and/CC
transcript/NN
reads/VBZ
./.
====================
Further/RB
,/,
we/PRP
surveyed/VBD
gene/NN
ontology/NN
(/(
GO/NN
)/)
in/IN
the/DT
highest/JJS
TC/NN
and/CC
the/DT
lowest/JJS
TC/NN
genes/NNS
./.
====================
The/DT
most/JJS
frequent/JJ
GOs/NN
with/IN
the/DT
highest/JJS
TC/NN
were/VBD
neuronal-related/VBN
and/CC
cell/NN
projection/NN
organization/NN
related/JJ
./.
====================
The/DT
most/JJS
frequent/JJ
GOs/NN
with/IN
the/DT
lowest/JJS
TC/NN
were/VBD
wound-healing/VBG
related/JJ
and/CC
embryo/JJ
development/NN
related/JJ
./.
====================
We/PRP
expect/VBP
that/DT
our/PRP$
analysis/NN
contributes/VBZ
to/TO
estimating/VBG
TC/NN
in/IN
the/DT
diverse/JJ
species/NNS
and/CC
playing/VBG
a/DT
benevolent/JJ
role/NN
to/TO
the/DT
new/JJ
bioinformatic/JJ
analysis/NN
./.
====================
There/EX
have/VBP
been/VBN
various/JJ
experimental/JJ
studies/NNS
regarding/VBG
enzyme/NN
activity/NN
[/(
1,2/NN
]/)
./.
====================
Enzyme/NN
activity/NN
is/VBZ
defined/VBN
by/IN
a/DT
measure/NN
of/IN
the/DT
quantity/NN
of/IN
active/JJ
enzyme/NN
present/JJ
./.
====================
Most/JJS
enzyme/NN
activity/NN
studies/NNS
are/VBP
based/VBN
on/IN
in/IN
vitro/FW
experiments/NNS
./.
====================
This/DT
approach/NN
is/VBZ
a/DT
limited/JJ
method/NN
because/IN
it/PRP
does/VBZ
not/RB
contain/VB
in/IN
vivo/FW
situations/NNS
./.
====================
Our/PRP$
approach/NN
was/VBD
to/TO
introduce/VB
transcript/NN
capacity/NN
(/(
TC/NN
)/)
concept/VBP
and/CC
this/DT
concept/NN
has/VBZ
both/CC
resemblance/NN
and/CC
difference/NN
in/IN
comparison/NN
to/TO
the/DT
enzyme/NN
activity/NN
estimation/NN
./.
====================
It/PRP
can/MD
be/VB
considered/VBN
that/IN
TC/NN
plays/VBZ
a/DT
role/NN
like/IN
enzyme/NN
activity/NN
as/IN
transcript/NN
activity/NN
or/CC
TC/NN
but/CC
it/PRP
is/VBZ
mainly/RB
related/JJ
to/TO
the/DT
analyzed/VBN
traits/VBZ
./.
====================
Thus/RB
,/,
TC/NN
does/VBZ
not/RB
match/VB
to/TO
the/DT
concept/NN
of/IN
enzyme/NN
activity/NN
,/,
perfectly/RB
./.
====================
Although/IN
enzyme/NN
activity/NN
is/VBZ
not/RB
directly/RB
associated/VBN
with/IN
TC/NN
,/,
the/DT
investigation/NN
of/IN
TC/NN
can/MD
be/VB
one/CD
of/IN
the/DT
important/JJ
route/JJ
to/TO
examine/VB
enzyme/NN
activity/NN
because/IN
both/CC
deal/JJ
with/IN
the/DT
capacity/NN
of/IN
specific/JJ
cellular/JJ
units/NNS
,/,
i.e/FW
./.
====================
enzyme/NN
and/CC
transcript/NN
./.
====================
We/PRP
calculated/VBD
TC/NN
using/VBG
the/DT
genome-wide/NN
association/NN
study/NN
(/(
GWAS/NN
)/)
beta/NN
effect/NN
and/CC
transcript/NN
reads/VBZ
in/IN
RNA-sequencing/JJ
(/(
RNA-seq/NN
)/)
data/NNS
,/,
and/CC
our/PRP$
study/NN
is/VBZ
based/VBN
on/IN
an/DT
in/FW
silico/NN
analysis/NN
./.
====================
Our/PRP$
novel/JJ
approach/NN
was/VBD
based/VBN
on/IN
that/DT
gene/NN
effect/NN
could/MD
be/VB
a/DT
function/NN
of/IN
TC/NN
and/CC
transcript/NN
reads/VBZ
./.
====================
TC/NN
refers/VBZ
to/TO
the/DT
capacity/NN
that/DT
one/CD
unit/NN
of/IN
transcripts/NNS
exerts/VBZ
as/IN
a/DT
cellular/JJ
function/NN
./.
====================
TC/NN
can/MD
not/RB
be/VB
easily/RB
measured/VBN
in/IN
experiments/NNS
./.
====================
We/PRP
calculated/VBD
TC/NN
using/VBG
bioinformatics/NNS
studies/NNS
./.
====================
GWAS/NN
can/MD
be/VB
used/VBN
for/IN
finding/NN
significant/JJ
variants/NNS
and/CC
genes/NNS
associated/VBN
with/IN
given/VBN
traits/VBZ
./.
====================
It/PRP
is/VBZ
a/DT
very/RB
efficient/JJ
and/CC
powerful/JJ
method/NN
for/IN
detecting/VBG
genes/NNS
of/IN
significance/NN
./.
====================
GWAS/NN
has/VBZ
been/VBN
used/VBN
to/TO
discover/JJ
disease-associated/JJ
genes/NNS
and/CC
quantitative/JJ
trait/NN
loci/NNS
genes/NNS
[/(
3-5/CD
]/)
./.
====================
Lu/NN
et/FW
al/JJ
./.
====================
[/(
6/CD
]/)
tried/VBD
to/TO
discover/JJ
new/JJ
loci/NNS
associated/VBN
with/IN
body/NN
fat/NN
percent/NN
(/(
BF/NN
%/NN
)/)
and/CC
identified/VBD
cardiometabolic/JJ
disease/NN
risk/NN
genomic/JJ
factors/NNS
./.
====================
For/IN
TC/NN
estimation/NN
,/,
we/PRP
used/VBD
BF/NN
%/NN
as/IN
the/DT
phenotype/NN
and/CC
performed/VBN
GWAS/NN
./.
====================
The/DT
beta/NN
effect/NN
in/IN
GWAS/NN
denotes/VBZ
the/DT
coefficient/JJ
of/IN
the/DT
regression/NN
model/NN
and/CC
it/PRP
can/MD
be/VB
the/DT
additive/JJ
effect/NN
of/IN
the/DT
single/JJ
nucleotide/NN
polymorphism/NN
(/(
SNP/NN
)/)
in/IN
the/DT
GWAS/NN
[/(
7-9/CD
]/)
./.
====================
The/DT
significant/JJ
markers/NNS
associated/VBN
with/IN
phenotypes/NNS
have/VBP
been/VBN
used/VBN
as/IN
the/DT
significance/NN
of/IN
the/DT
encompassed/VBN
genes/NNS
in/IN
GWAS/NN
./.
====================
This/DT
is/VBZ
plausible/JJ
because/IN
SNPs/NNS
is/VBZ
linked/VBN
at/IN
those/DT
encompassing/VBG
genes/NNS
which/WDT
are/VBP
usually/RB
called/VBN
“/NN
linkage/NN
disequilibrium/NN
./.
”/CD
====================
RNA-seq/NN
data/NNS
provides/VBZ
transcripts/NNS
’/CD
reads/VBZ
[/(
10,11/CD
]/)
./.
====================
Through/IN
transcript/NN
reads/VBZ
and/CC
gene/NN
effects/NNS
,/,
we/PRP
calculated/VBD
TC/NN
./.
====================
TC/NN
analysis/NN
can/MD
be/VB
important/JJ
because/IN
it/PRP
can/MD
be/VB
further/RBR
analyzed/VBD
the/DT
enzyme/NN
activity/NN
if/IN
the/DT
protein/NN
expression/NN
level/NN
instead/RB
of/IN
transcript/NN
reads/VBZ
is/VBZ
given/VBN
./.
====================
Data/NNS
description/NN
====================
For/IN
GWAS/NN
,/,
we/PRP
used/VBD
Ansan-Anseong/JJ
cohort/NN
data/NNS
./.
====================
These/DT
were/VBD
for/IN
a/DT
study/NN
of/IN
a/DT
chronic/JJ
diseases/NNS
within/IN
Ansan/NN
city/NN
and/CC
Anseong/JJ
rural/JJ
areas/NNS
in/IN
Korea/NN
./.
====================
The/DT
dataset/NN
comprised/VBD
men/NNS
(/(
8,842/CD
people/NN
)/)
between/IN
40–69/CD
years/NNS
of/IN
age/NN
who/WP
had/VBD
been/VBN
residents/NNS
of/IN
the/DT
region/NN
for/IN
at/IN
least/JJS
6/CD
months/NNS
[/(
12,13/CD
]/)
./.
====================
Our/PRP$
study/NN
was/VBD
from/IN
the/DT
3rd/JJ
Ansan-Anseong/JJ
cohort/NN
dataset/NN
version/NN
2.1/CD
./.
====================
The/DT
analyzed/VBN
phenotypes/NNS
were/VBD
BF/NN
%/NN
unit/NN
and/CC
the/DT
covariates/NNS
were/VBD
set/NN
to/TO
be/VB
area/NN
,/,
age/NN
and/CC
sex/NN
./.
====================
The/DT
SNP/NN
dataset/NN
was/VBD
implemented/VBN
using/VBG
Affymetrix/JJ
Genome-wide/NN
Human/JJ
SNP/NN
Array/NN
5.0/CD
(/(
Affymetrix/JJ
,/,
Santa/NN
Clara/NN
,/,
CA/NN
,/,
USA/NN
)/)
./.
====================
The/DT
mean/JJ
call/JJ
rate/NN
was/VBD
99.01/CD
%/NN
./.
====================
The/DT
total/JJ
number/NN
of/IN
SNPs/NNS
was/VBD
352,228/CD
and/CC
after/IN
quality/NN
control/NN
(/(
minor/JJ
allele/NN
frequency/NN
</JJR
0.05/CD
,/,
Hardy-Weinberg/JJ
equilibrium/NN
p-value/NN
</JJR
0.0001/CD
and/CC
missing/VBG
genotype/NN
rate/NN
>/JJR
0.05/CD
)/)
,/,
308,003/CD
SNPs/NNS
were/VBD
left/RB
./.
====================
For/IN
transcript/NN
reads/VBZ
,/,
we/PRP
used/VBD
transcript/NN
reads/VBZ
per/FW
million/NN
(/(
TPM/NN
)/)
data/NNS
at/IN
the/DT
following/VBG
website/JJ
(/(
http/NN
:/:
//www.proteinatlas.org/JJ
)/)
./.
====================
The/DT
Human/JJ
Protein/NN
Atlas/NNS
was/VBD
released/VBN
with/IN
protein/NN
profile/NN
data/NNS
covering/VBG
48/CD
different/JJ
human/JJ
tissues/NNS
and/CC
organs/NNS
,/,
including/VBG
adipocytes/NNS
,/,
the/DT
kidney/NN
and/CC
the/DT
liver/NN
[/(
14,15/CD
]/)
./.
====================
Among/IN
these/DT
organs/NNS
,/,
we/PRP
used/VBD
adipocyte/NN
’/CD
s/NNS
transcript/NN
reads/VBZ
data/NNS
./.
====================
The/DT
TPM/NN
data/NNS
of/IN
the/DT
Human/JJ
Protein/NN
atlas/NNS
is/VBZ
based/VBN
on/IN
the/DT
reads/VBZ
per/FW
gene/NN
./.
====================
Thus/RB
the/DT
gene/NN
length/NN
was/VBD
pre-considered/VBN
for/IN
the/DT
accurate/JJ
reads/VBZ
estimation/NN
per/FW
gene/NN
./.
====================
Genome-wide/NN
association/NN
study/NN
(/(
GWAS/NN
)/)
====================
GWAS/NN
was/VBD
performed/VBN
using/VBG
GCTA/NN
(/(
a/DT
tool/NN
for/IN
genome-wide/NN
complex/NN
trait/VBP
analysis/NN
)/)
to/TO
estimate/VB
the/DT
beta/NN
effects/NNS
[/(
9,16/CD
]/)
./.
====================
The/DT
following/VBG
model/NN
was/VBD
:/:
====================
(/(
1/CD
)/)
y/RB
=/JJ
a/DT
+/JJ
b/NN
x/NN
+/JJ
g/NN
+/JJ
e/NN
====================
where/WRB
y/RB
is/VBZ
the/DT
phenotypic/JJ
value/NN
(/(
BF/NN
%/NN
)/)
,/,
a/DT
is/VBZ
the/DT
mean/JJ
term/NN
,/,
b/LS
is/VBZ
the/DT
additive/JJ
beta/NN
effect/NN
of/IN
the/DT
candidate/NN
SNP/NN
for/IN
association/NN
,/,
x/CC
is/VBZ
the/DT
SNP/NN
genotype/NN
indicator/NN
variable/JJ
,/,
g/NN
is/VBZ
the/DT
polygenic/JJ
effect/NN
,/,
and/CC
e/NN
is/VBZ
the/DT
residual/JJ
./.
====================
The/DT
covariates/NNS
were/VBD
sex/NN
(/(
male/JJ
and/CC
female/JJ
)/)
,/,
area/NN
(/(
Ansan/NN
and/CC
Anseong/JJ
)/)
and/CC
age/NN
./.
====================
The/DT
age/NN
was/VBD
factored/VBN
to/TO
be/VB
10-age/CD
steps/NNS
./.
====================
The/DT
b/NN
was/VBD
the/DT
beta/NN
effect/NN
of/IN
the/DT
SNPs/NNS
./.
====================
TC/NN
calculation/NN
====================
TC/NN
was/VBD
calculated/VBN
using/VBG
the/DT
following/VBG
relationships/NNS
:/:
====================
(/(
2/CD
)/)
TC/NN
=/JJ
effect/NN
of/IN
gene/NN
t/NN
r/NN
a/DT
n/NN
s/NNS
c/NN
r/NN
i/LS
p/NN
t/NN
r/NN
e/NN
a/DT
d/FW
s/NNS
====================
Eq/NN
./.
====================
(/(
2/CD
)/)
uses/VBZ
the/DT
gene/NN
effect/NN
and/CC
transcript/NN
reads/VBZ
(/(
TPM/NN
)/)
to/TO
determine/VB
the/DT
TC/NN
./.
====================
We/PRP
assumed/VBD
that/IN
the/DT
effect/NN
of/IN
the/DT
gene/NN
was/VBD
proportional/JJ
to/TO
the/DT
transcript/NN
reads/VBZ
and/CC
TC/NN
./.
====================
The/DT
gene/NN
effect/NN
is/VBZ
proportional/JJ
to/TO
TC/NN
as/IN
given/VBN
in/IN
Eq/NN
./.
====================
(/(
2/CD
)/)
./.
====================
If/IN
A/DT
and/CC
B/NN
genes/NNS
’/CD
effect/NN
is/VBZ
10/CD
,/,
10/CD
,/,
respectively/RB
and/CC
transcript/NN
reads/VBZ
are/VBP
1,000/CD
and/CC
10,000/CD
,/,
then/RB
TCs/NNS
of/IN
A/DT
and/CC
B/NN
are/VBP
0.01/CD
and/CC
0.001/CD
./.
====================
Thus/RB
the/DT
capacity/NN
of/IN
the/DT
A/NN
transcript/NN
is/VBZ
10-fold/JJ
stronger/JJR
than/IN
B/NN
transcript/NN
./.
====================
One/CD
unit/NN
of/IN
A/DT
transcripts/NNS
influences/VBZ
10-fold/JJ
to/TO
the/DT
traits/NNS
in/IN
comparison/NN
to/TO
the/DT
B/NN
transcripts/NNS
./.
====================
Gene/NN
ontology/NN
analysis/NN
====================
The/DT
gene/NN
ontology/NN
(/(
GO/NN
)/)
analysis/NN
was/VBD
performed/VBN
using/VBG
DAVID/NN
(/(
Database/NN
for/IN
Annotation/NN
,/,
Visualization/NN
and/CC
Integrated/JJ
Discovery/NN
)/)
[/(
17/CD
]/)
./.
====================
The/DT
gene/NN
catalogue/NN
was/VBD
retrieved/VBN
from/IN
Ensembl/NN
DB/NN
(/(
http/NN
:/:
//www.ensembl.org/JJ
)/)
./.
====================
We/PRP
selected/VBD
the/DT
genes/NNS
with/IN
the/DT
highest/JJS
and/CC
lowest/JJS
TC/NN
(/(
top/NN
and/CC
bottom/CC
5/CD
%/NN
in/IN
TC/NN
values/NNS
)/)
for/IN
the/DT
GO/NN
analysis/NN
./.
====================
Figure/NN
description/NN
====================
Fig/NN
./.
====================
1/CD
shows/VBZ
the/DT
flow/NN
chart/NN
of/IN
our/PRP$
analysis/NN
./.
====================
It/PRP
explains/VBZ
the/DT
procedure/NN
of/IN
the/DT
TC/NN
calculation/NN
./.
====================
The/DT
gene/NN
effect/NN
was/VBD
calculated/VBN
using/VBG
GWAS/JJ
and/CC
TC/NN
was/VBD
calculated/VBN
using/VBG
gene/NN
effect/NN
and/CC
TPM/NN
./.
====================
As/IN
shown/VBN
in/IN
Eq/NN
./.
====================
(/(
2/CD
)/)
,/,
the/DT
TC/NN
unit/NN
in/IN
our/PRP$
analysis/NN
is/VBZ
BF/NN
%/NN
./.
====================
Fig/NN
./.
====================
2/CD
shows/VBZ
the/DT
plot/NN
of/IN
TPM/NN
and/CC
GWAS/NN
beta/NN
effect/NN
./.
====================
The/DT
genes/NNS
with/IN
a/DT
higher/JJR
TPM/NN
had/VBD
a/DT
smaller/JJR
beta/NN
effect/NN
across/IN
the/DT
board/JJ
./.
====================
According/VBG
to/TO
Eq/NN
./.
====================
(/(
2/CD
)/)
,/,
a/DT
higher/JJR
TPM/NN
and/CC
a/DT
smaller/JJR
beta/NN
effect/NN
would/MD
show/VB
a/DT
smaller/JJR
TC/NN
./.
====================
Fig/NN
./.
====================
3/CD
shows/VBZ
the/DT
Manhattan/JJ
plot/NN
of/IN
–log10/CD
(/(
p-value/NN
)/)
and/CC
the/DT
TC/NN
across/IN
chromosomes/NNS
./.
====================
The/DT
p-value/JJ
was/VBD
from/IN
GWAS/NN
results/NNS
and/CC
TC/NN
was/VBD
calculated/VBN
as/IN
shown/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
TC/NN
calculation/NN
and/CC
GO/NN
analysis/NN
====================
Table/JJ
1/CD
shows/VBZ
the/DT
summary/NN
statistics/NNS
(/(
minimum/JJ
,/,
maximum/NN
,/,
average/NN
,/,
standard/JJ
deviation/NN
)/)
of/IN
GWAS/NN
beta/NN
effect/NN
,/,
TPM/NN
and/CC
TC/NN
./.
====================
Table/JJ
2./FW
shows/VBZ
the/DT
gene/NN
information/NN
with/IN
the/DT
lowest/JJS
p-values/NNS
(/(
</JJR
0.0001/CD
)/)
and/CC
the/DT
estimated/VBN
TC/NN
./.
====================
The/DT
TC/NN
was/VBD
simply/RB
calculated/VBN
using/VBG
Eq/JJ
./.
====================
(/(
2/CD
)/)
./.
====================
Table/JJ
3/CD
illustrates/VBZ
genes/NNS
’/CD
TC/NN
information/NN
of/IN
the/DT
highest/JJS
p-values/NNS
(/(
top/NN
5/CD
%/NN
genes/NNS
in/IN
TC/NN
value/NN
)/)
./.
====================
The/DT
neuronal/JJ
genes/NNS
including/VBG
neuronal-activity/NN
regulated/VBN
genes/NNS
have/VBP
important/JJ
functions/NNS
in/IN
dendrites/NNS
and/CC
synapses/NNS
and/CC
are/VBP
likely/JJ
to/TO
regulate/VB
circuit/NN
connectivity/NN
directly/RB
./.
====================
Thus/RB
for/IN
the/DT
easy/JJ
regulation/NN
of/IN
circuit/JJ
connectivity/NN
,/,
they/PRP
might/MD
have/VB
the/DT
strategy/NN
through/IN
possessing/JJ
low/JJ
transcript/NN
reads/VBZ
and/CC
high/JJ
TC/NN
[/(
18/CD
]/)
./.
====================
Brain-derived/JJ
neurotrophic/JJ
factor/NN
(/(
BDNF/NN
;/:
TC/NN
,/,
1.88/CD
BF/NN
%/NN
)/)
encodes/VBZ
a/DT
neurotrophin/NN
that/DT
is/VBZ
secreted/VBN
at/IN
the/DT
synapse/NN
./.
====================
The/DT
induction/NN
of/IN
BDNF/NN
promotes/VBZ
both/CC
synapse/NN
maturation/NN
and/CC
dendritic/JJ
growth/NN
./.
====================
BDNF/NN
had/VBD
high/JJ
TC/NN
and/CC
its/PRP$
mutation/NN
can/MD
cause/VB
neurological/JJ
and/CC
psychiatric/JJ
disorders/NNS
[/(
18/CD
]/)
./.
====================
Table/JJ
4/CD
shows/VBZ
the/DT
GO/NN
with/IN
the/DT
lowest/JJS
TC/NN
(/(
bottom/CC
5/CD
%/NN
genes/NNS
)/)
./.
====================
It/PRP
shows/VBZ
that/IN
the/DT
lowest/JJS
TC/NN
’/CD
s/NNS
major/JJ
GO/NN
terms/NNS
were/VBD
endoderm/JJ
formation/NN
,/,
wound/NN
healing/NN
and/CC
embryo/JJ
development/NN
./.
====================
The/DT
von/NN
Willebrand/NN
factor/NN
(/(
VWF/NN
)/)
is/VBZ
not/RB
an/DT
enzyme/NN
and/CC
thus/RB
,/,
has/VBZ
no/DT
catalytic/JJ
activity/NN
(/(
https/NNS
:/:
//en.wikipedia.org/wiki/Von_Willebrand_factor/NN
)/)
./.
====================
In/IN
our/PRP$
analysis/NN
,/,
the/DT
VWF/NN
had/VBD
high/JJ
transcript/NN
reads/VBZ
and/CC
low/JJ
TC/NN
(/(
TPM/NN
,/,
155.1/NN
;/:
TC/NN
,/,
0.002/CD
BF/NN
%/NN
)/)
./.
====================
GWAS/NN
and/CC
expression/NN
quantitative/JJ
trait/NN
loci/NNS
====================
We/PRP
used/VBD
the/DT
GWAS/NN
and/CC
RNA-seq/NN
data/NNS
associated/VBN
with/IN
body/NN
fat/NN
./.
====================
The/DT
expression/NN
quantitative/JJ
trait/NN
loci/NNS
(/(
eQTL/NN
)/)
are/VBP
genomic/JJ
loci/NNS
that/IN
explain/VBP
a/DT
variation/NN
in/IN
expression/NN
levels/NNS
of/IN
mRNAs/NNS
(/(
https/NNS
:/:
//en.wikipedia.org/wiki/Expression_quantitative_trait_loci/NNS
)/)
./.
====================
Parks/NNS
et/FW
al/JJ
./.
====================
[/(
19/CD
]/)
showed/VBD
the/DT
genetic/JJ
control/NN
of/IN
obesity/NN
and/CC
gut/NN
microbiota/NNS
composition/NN
using/VBG
eQTL/NN
analysis/NN
./.
====================
In/IN
our/PRP$
analysis/NN
,/,
the/DT
accurate/JJ
beta/NN
effect/NN
estimation/NN
accompanied/VBN
by/IN
p-value/JJ
are/VBP
crucial/JJ
and/CC
thus/RB
eQTL/NN
analysis/NN
can/MD
help/VB
better/RBR
estimating/VBG
TC/NN
because/IN
eQTL/NN
information/NN
contains/VBZ
the/DT
mRNA/NN
expression/NN
level/NN
./.
====================
GWAS/NN
p-value/NN
and/CC
accuracy/NN
of/IN
TC/NN
calculation/NN
====================
In/IN
GWASs/NNS
,/,
the/DT
significance/NN
is/VBZ
guaranteed/JJ
by/IN
the/DT
p-value/NN
./.
====================
The/DT
p-value/JJ
is/VBZ
the/DT
criteria/NNS
to/TO
dissect/VB
the/DT
significant/JJ
variants/NNS
and/CC
those/DT
genes/NNS
from/IN
insignificant/JJ
ones/NNS
./.
====================
Although/IN
genes/NNS
’/CD
effects/NNS
were/VBD
dissected/VBN
by/IN
the/DT
p-value/NN
,/,
only/RB
the/DT
beta/NN
effect/NN
was/VBD
used/VBN
for/IN
TC/NN
calculation/NN
./.
====================
The/DT
gene/NN
’/CD
s/NNS
GWAS/NN
p-value/NN
and/CC
beta/NN
effect/NN
can/MD
be/VB
varied/VBN
with/IN
respect/NN
to/TO
analyzed/VBN
phenotypes/NNS
./.
====================
The/DT
highly/RB
accurate/VBP
TC/NN
calculation/NN
should/MD
be/VB
certified/VBN
by/IN
using/VBG
diverse/JJ
phenotypes/NNS
in/IN
GWAS/NN
./.
====================
Additionally/RB
,/,
the/DT
transcript/NN
reads/VBZ
in/IN
RNA-seq/NN
data/NNS
can/MD
be/VB
diverse/JJ
in/IN
various/JJ
tissues/NNS
./.
====================
By/IN
using/VBG
diverse/JJ
tissues/NNS
and/CC
information/NN
from/IN
various/JJ
traits/VBZ
,/,
the/DT
accurate/JJ
TC/NN
calculation/NN
can/MD
be/VB
plausible/JJ
for/IN
generally/RB
acceptable/JJ
estimation/NN
./.
====================
BF/NN
%/NN
can/MD
be/VB
used/VBN
to/TO
approximate/VB
fat/NN
accumulation/NN
in/IN
adipose/NN
tissues/NNS
./.
====================
The/DT
trait/NN
reflects/VBZ
the/DT
fat/NN
accumulation/NN
and/CC
the/DT
gene/NN
’/CD
s/NNS
play/VBP
in/IN
adipose/NN
tissue/NN
./.
====================
The/DT
GWAS/NN
directs/VBZ
the/DT
significant/JJ
variants/NNS
associated/VBN
with/IN
body/NN
fat/NN
but/CC
the/DT
TC/NN
quantity/NN
only/RB
mirrors/NNS
the/DT
transcript/NN
activity/NN
only/RB
related/JJ
to/TO
the/DT
analyzed/VBN
traits/VBZ
as/IN
indicated/VBD
by/IN
TC/NN
unit/NN
(/(
BF/NN
%/NN
)/)
./.
====================
Our/PRP$
GWAS/NN
calculation/NN
for/IN
the/DT
gene/NN
effect/NN
was/VBD
based/VBN
on/IN
the/DT
linkage/NN
disequilibrium/NN
between/IN
SNP/NN
markers/NNS
and/CC
the/DT
gene/NN
./.
====================
Despite/IN
the/DT
advantages/NNS
of/IN
GWAS/NN
using/VBG
SNP/NN
markers/NNS
,/,
diverse/JJ
SNP/NN
markers/NNS
per/IN
gene/NN
can/MD
cause/VB
a/DT
problem/NN
./.
====================
Thus/RB
gene-based/VBN
GWAS/NN
can/MD
be/VB
an/DT
another/DT
alternative/JJ
method/NN
./.
====================
And/CC
RNA-seq/NN
data/NNS
had/VBD
better/RBR
be/VB
obtained/VBN
from/IN
the/DT
similar/JJ
sample/NN
to/TO
the/DT
GWAS/NN
dataset/NN
./.
====================
The/DT
neuronal/JJ
and/CC
cell/NN
projection/NN
organization/NN
genes/NNS
were/VBD
enriched/VBN
in/IN
the/DT
GO/NN
analysis/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
These/DT
genes/NNS
have/VBP
low/JJ
p-values/NNS
in/IN
the/DT
GWAS/NN
analysis/NN
of/IN
BF/NN
%/NN
across/IN
the/DT
board/JJ
./.
====================
Inspecting/VBG
the/DT
relationship/NN
between/IN
TC/NN
and/CC
GO/NN
terms/NNS
why/WRB
the/DT
lowest/JJS
TC/NN
values/NNS
are/VBP
associated/VBN
with/IN
certain/JJ
GO/NN
terms/NNS
,/,
is/VBZ
a/DT
subject/JJ
that/DT
needs/VBZ
to/TO
be/VB
addressed/VBN
./.
====================
Likewise/RB
,/,
the/DT
reason/NN
why/WRB
wound/NN
healing/NN
and/CC
embryo/JJ
development/NN
GO/NN
terms/NNS
have/VBP
low/JJ
TC/NN
values/NNS
must/MD
be/VB
elucidated/VBN
./.
====================
Features/NNS
of/IN
the/DT
TC/NN
calculation/NN
in/IN
our/PRP$
study/NN
====================
Unlike/IN
previous/JJ
studies/NNS
that/IN
calculate/JJ
the/DT
protein/NN
activity/NN
,/,
TC/NN
calculation/NN
is/VBZ
a/DT
high-throughput/JJ
analysis/NN
./.
====================
Vermeirssen/RB
et/FW
al/JJ
./.
====================
[/(
20/CD
]/)
used/VBN
a/DT
quantitative/JJ
in/IN
silico/NN
analysis/NN
to/TO
calculate/JJ
the/DT
inhibitory/JJ
activity/NN
of/IN
angiotensin/NN
I/NN
converting/VBG
enzyme/NN
(/(
ACE/NN
)/)
./.
====================
They/PRP
used/VBN
an/DT
in/FW
vivo/FW
analysis/NN
to/TO
calculate/VB
ACE/NN
activity/NN
,/,
also/RB
./.
====================
Our/PRP$
study/NN
to/TO
calculate/VB
TC/NN
is/VBZ
theoretically/RB
novel/JJ
./.
====================
Additionally/RB
,/,
it/PRP
is/VBZ
feasible/JJ
not/RB
only/RB
to/TO
calculate/JJ
TC/NN
,/,
but/CC
also/RB
to/TO
calculate/JJ
other/JJ
annotated/JJ
ones/NNS
including/VBG
transcription/NN
factor/NN
whose/WP$
activity/NN
can/MD
not/RB
be/VB
easily/RB
measured/VBN
experimentally/RB
./.
====================
The/DT
flow/NN
chart/NN
of/IN
the/DT
analysis/NN
./.
====================
The/DT
transcript/NN
capacity/NN
was/VBD
calculated/VBN
in/IN
silico/NN
using/VBG
genome-wide/NN
association/NN
study/NN
(/(
GWAS/NN
)/)
and/CC
RNA-sequencing/JJ
(/(
RNA-seq/NN
)/)
./.
====================
SNP/NN
,/,
single/JJ
nucleotide/NN
polymorphism/NN
;/:
TA/NN
,/,
transcript/NN
activity/NN
(/(
synonym/NN
:/:
transcript/NN
capacity/NN
)/)
;/:
TPM/NN
,/,
transcript/NN
per/IN
million/NN
reads/VBZ
./.
====================
Transcript/NN
reads/VBZ
per/FW
million/NN
(/(
TPM/NN
)/)
versus/CC
genome-wide/NN
association/NN
study/NN
(/(
GWAS/NN
)/)
beta/NN
effect/NN
./.
====================
Larger/NN
beta/NN
effect/NN
genes/NNS
had/VBD
a/DT
smaller/JJR
TPM/NN
across/IN
the/DT
board/JJ
./.
====================
The/DT
Manhattan/JJ
plot/NN
of–log10/CD
(/(
p-value/NN
)/)
including/VBG
total/JJ
analyzed/VBD
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
(/(
A/DT
)/)
and/CC
transcript/NN
capacity/NN
(/(
TC/NN
)/)
(/(
B/NN
)/)
under/IN
p-value/JJ
</JJR
0.05/CD
across/IN
chromosomes/NNS
./.
====================
The/DT
P-value/JJ
was/VBD
obtained/VBN
from/IN
the/DT
genome-wide/NN
association/NN
study/NN
(/(
GWAS/NN
)/)
of/IN
the/DT
SNPs/NNS
and/CC
those/DT
encompassing/VBG
genes/NNS
./.
====================
TC/NN
was/VBD
calculated/VBN
using/VBG
the/DT
GWAS/NN
beta/NN
effect/NN
and/CC
transcript/NN
per/IN
million/NN
reads/VBZ
./.
====================
Summary/JJ
statistics/NNS
of/IN
beta/NN
effect/NN
,/,
TPM/NN
,/,
and/CC
TC/NN
in/IN
our/PRP$
analysis/NN
====================
Genes/NNS
with/IN
the/DT
lowest/JJS
p-values/NNS
(/(
cutoff/JJ
0.0001/CD
)/)
and/CC
their/PRP$
TC/NN
estimation/NN
====================
GO/NN
for/IN
the/DT
highest/JJS
(/(
as/IN
TC/NN
values/NNS
)/)
top/NN
1/CD
%/NN
of/IN
the/DT
genes/NNS
====================
GO/NN
for/IN
the/DT
lowest/JJS
(/(
as/IN
TC/NN
values/NNS
)/)
bottom/CC
1/CD
%/NN
of/IN
the/DT
genes/NNS
====================
